



Pulmonary Arterial Hypertension (PAH)

Guest Editor:

Dr. Allan Lawrie

Department of Cardiovascular
Science, University of Sheffield,
Sheffield, UK

Deadline for manuscript
submissions:

closed (15 February 2014)

Message from the Guest Editor

Dear Colleagues,

Pulmonary arterial hypertension (PAH) is a rare but devastating disease that carries a terrible prognosis. Pathologically PAH is characterized by sustained vasoconstriction and progressive obliteration of small resistance pulmonary arteries. Current treatments target the sustained vasoconstriction but the prognosis remains poor. There is currently limited information on biomarkers that indicate a patient response to these therapies. There is also an unmet need to develop new treatments that specifically target the progressive vasculopathy in these patients.

This Special Issue will provide an Open Access opportunity to publish research work and review articles related to the novel biomarkers, new molecular insights and potential therapeutic targets.

Dr. Allan Lawrie

Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Maurizio Battino

Department of
Odontostomatologic and
Specialized Clinical Sciences,
Sez-Biochimica, Faculty of
Medicine, Università Politecnica
delle Marche, Via Ranieri 65,
60100 Ancona, Italy

Message from the Editor-in-Chief

Diseases is an international, peer-reviewed, open access, multidisciplinary journal that focuses on the latest outstanding research concerning diseases and conditions. Research articles, reviews, and other contents are released on the Internet immediately after acceptance. This journal aims to cover international conferences and symposia as new targets.

Diseases is increasingly gaining acceptance and visibility within scholars, and after only a few years of life, *Diseases* is now also covering specific topics with dedicated special issues. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High visibility: indexed within Scopus, ESCI (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Rapid Publication: manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.8 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the second half of 2023).

Contact Us

Diseases Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/diseases
diseases@mdpi.com
X@Diseases_MDPI